Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD

8.08

-0.09 (-1.10%)

At close: Nov 10, 2026, 4:00 PM EST

8.07

-0.01 (-0.12%)

After-hours: Nov 10, 2026, 6:45 PM EST

Iovance Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	378.98	263.5	164.07	1.19	-	-
Revenue Growth	51.34%	60.60%	13698.99%	-	-	-
Cost of Revenue	177.23	173.18	93.25	1.03	-	-
Gross Profit	201.75	90.32	70.82	0.16	-	-
Selling, General & Admin	153.2	152.32	152.27	106.1	104.1	83.66
Research & Development	241.88	300.27	276.23	333.19	294.78	259.04
Operating Expenses	432.13	488.53	466.1	460.72	398.88	342.7
Operating Income	-230.38	-398.21	-395.28	-460.56	-398.88	-342.7
Interest & Investment Income	2.94	3.11	4.51	9.44	3.46	6.46
EBT Excluding Unusual Items	-227.44	-395.11	-390.77	-451.12	-395.42	-336.24
Merger & Restructuring Charges	-	-5.14	-	-	-	-
Gain (Loss) on Sale of Investments	5.66	7.2	10.26	3.61	-0.47	-6.01
Other Unusual Items	-	-	5.5	-	-	-
Pretax Income	-221.78	-393.05	-375.01	-447.52	-395.89	-342.25
Income Tax Expense	-1.24	-2.07	-2.83	-3.48	-	-
Net Income	-220.54	-390.98	-372.18	-444.04	-395.89	-342.25
Net Income to Common	-220.54	-390.98	-372.18	-444.04	-395.89	-342.25
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	434	357	290	235	159	153
Shares Outstanding (Diluted)	434	357	290	235	159	153
Shares Change	30.80%	23.28%	23.28%	47.64%	3.82%	10.92%
EPS (Basic)	-0.51	-1.09	-1.28	-1.89	-2.49	-2.23
EPS (Diluted)	-0.51	-1.09	-1.28	-1.89	-2.49	-2.23
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-216.06	-336.24	-364.05	-384.11	-313.18	-265.52
Free Cash Flow Per Share	-0.50	-0.94	-1.26	-1.63	-1.97	-1.73
Gross Margin	53.23%	34.28%	43.17%	13.12%	-	-
Operating Margin	-60.79%	-151.12%	-240.92%	-38734.99%	-	-
Profit Margin	-58.19%	-148.38%	-226.84%	-37345.42%	-	-
Free Cash Flow Margin	-57.01%	-127.61%	-221.89%	-32305.30%	-	-
EBITDA	-192.91	-362.27	-357.64	-439.14	-389.57	-339.59
EBITDA Margin	-50.90%	-137.48%	-217.98%	-	-	-
D&A For EBITDA	37.47	35.94	37.63	21.42	9.31	3.11
EBIT	-230.38	-398.21	-395.28	-460.56	-398.88	-342.7
EBIT Margin	-60.79%	-151.12%	-240.92%	-	-	-
Revenue as Reported	378.98	263.5	164.07	1.19	-	-

SEC Filings: 10-K · 10-Q